TY - JOUR
T1 - The broccoli-derived antioxidant sulforaphane changes the growth of gastrointestinal microbiota, allowing for the production of anti-inflammatory metabolites
AU - Young, Remy B.
AU - Lewis, Jessica M.
AU - Rutten, Emily L.
AU - Gould, Jodee
AU - Barlow, Christopher K.
AU - Giogha, Cristina
AU - Marcelino, Vanessa R.
AU - Fields, Neville
AU - Schittenhelm, Ralf B.
AU - Hartland, Elizabeth L.
AU - Scott, Nichollas E.
AU - Forster, Samuel C.
A2 - Marshall, Sarah A.
A2 - Gulliver, Emily L.
N1 - Funding Information:
This work was supported by the C. Andrew Ramsden Collaborative Award 2020 awarded to ELG and SAM. SCF is supported by a CSL Centenary Fellowship, VRM is supported by an Australian Research Council DECRA Fellowship ( DE220100965 ). This work was supported by the Victorian Government Operational Infrastructure Support Scheme.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/8
Y1 - 2023/8
N2 - Sulforaphane is a naturally occurring, potent antioxidant, found in Brassicaceae plants such as broccoli, and is being considered for use in the treatment of fibrosis, cancer and preeclampsia. As sulforaphane is orally administered and has been shown to demonstrate antimicrobial properties in aerobic conditions, there is also the potential for impact on the gut microbiome under anaerobic conditions. Here, we have determined the effect of sulforaphane on the growth of 43 common human gastrointestinal microbiota, representing common commensals and pathogens. The enteropathogenic Escherichia coli strain EPEC E2348/69 showed the most significant increases in growth in the presence of sulforaphane. Proteomic analysis of this isolate showed that sulforaphane increased anaerobic respiration, whilst metabolomics identified differentially produced metabolites that can decrease inflammation in human cells. Therefore, sulforaphane can increase growth of specific gastrointestinal microbiota, correlating with increased production of anti-inflammatory metabolites. Thus, providing a novel mechanism for modulating inflammatory states in patients.
AB - Sulforaphane is a naturally occurring, potent antioxidant, found in Brassicaceae plants such as broccoli, and is being considered for use in the treatment of fibrosis, cancer and preeclampsia. As sulforaphane is orally administered and has been shown to demonstrate antimicrobial properties in aerobic conditions, there is also the potential for impact on the gut microbiome under anaerobic conditions. Here, we have determined the effect of sulforaphane on the growth of 43 common human gastrointestinal microbiota, representing common commensals and pathogens. The enteropathogenic Escherichia coli strain EPEC E2348/69 showed the most significant increases in growth in the presence of sulforaphane. Proteomic analysis of this isolate showed that sulforaphane increased anaerobic respiration, whilst metabolomics identified differentially produced metabolites that can decrease inflammation in human cells. Therefore, sulforaphane can increase growth of specific gastrointestinal microbiota, correlating with increased production of anti-inflammatory metabolites. Thus, providing a novel mechanism for modulating inflammatory states in patients.
KW - Anti-inflammatory
KW - Escherichia coli
KW - Metabolites
KW - Microbiota
KW - Sulforaphane
UR - http://www.scopus.com/inward/record.url?scp=85163454994&partnerID=8YFLogxK
U2 - 10.1016/j.jff.2023.105645
DO - 10.1016/j.jff.2023.105645
M3 - Article
AN - SCOPUS:85163454994
SN - 1756-4646
VL - 107
JO - Journal of Functional Foods
JF - Journal of Functional Foods
M1 - 105645
ER -
